[1]
McInnis M, Petursson H. Withdrawal of trihexyphenidyl. Acta psychiatrica Scandinavica. 1985 Mar:71(3):297-303
[PubMed PMID: 3984771]
[2]
Cui Y, Su D, Zhang J, Lam JST, Cao S, Yang Y, Piao Y, Wang Z, Zhou J, Pan H, Feng T. Dopaminergic versus anticholinergic treatment effects on physiologic complexity of hand tremor in Parkinson's disease: A randomized crossover study. CNS neuroscience & therapeutics. 2024 Apr:30(4):e14516. doi: 10.1111/cns.14516. Epub 2023 Oct 31
[PubMed PMID: 37905677]
Level 1 (high-level) evidence
[3]
Brocks DR. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 1999 May-Aug:2(2):39-46
[PubMed PMID: 10952768]
Level 3 (low-level) evidence
[4]
Wisidagama S, Selladurai A, Wu P, Isetta M, Serra-Mestres J. Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review. Medicines (Basel, Switzerland). 2021 May 26:8(6):. doi: 10.3390/medicines8060024. Epub 2021 May 26
[PubMed PMID: 34073269]
Level 3 (low-level) evidence
[5]
Feldman M, Marmol S, Margolesky J. Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic. Therapeutics and clinical risk management. 2022:18():1129-1142. doi: 10.2147/TCRM.S360268. Epub 2022 Dec 20
[PubMed PMID: 36573102]
Level 3 (low-level) evidence
[6]
Wubeshet YS, Mohammed OS, Desse TA. Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study. BMC psychiatry. 2019 Jan 18:19(1):32. doi: 10.1186/s12888-018-1999-x. Epub 2019 Jan 18
[PubMed PMID: 30658604]
Level 2 (mid-level) evidence
[7]
Harvey AR, Baker LB, Reddihough DS, Scheinberg A, Williams K. Trihexyphenidyl for dystonia in cerebral palsy. The Cochrane database of systematic reviews. 2018 May 15:5(5):CD012430. doi: 10.1002/14651858.CD012430.pub2. Epub 2018 May 15
[PubMed PMID: 29763510]
Level 1 (high-level) evidence
[8]
Yadav SK, Yadav P, Maharjan G, Dahal S, Khati N. Status Dystonicus with Atypical Presentation in Developmentally Delay Child: A Case Report. JNMA; journal of the Nepal Medical Association. 2022 Aug 1:60(252):739-742. doi: 10.31729/jnma.7614. Epub 2022 Aug 1
[PubMed PMID: 36705216]
Level 3 (low-level) evidence
[9]
Giachetti A, Giraldo E, Ladinsky H, Montagna E. Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. British journal of pharmacology. 1986 Sep:89(1):83-90
[PubMed PMID: 2432979]
[10]
Berke JD, Hyman SE. Addiction, dopamine, and the molecular mechanisms of memory. Neuron. 2000 Mar:25(3):515-32
[PubMed PMID: 10774721]
[11]
Robottom BJ, Reich SG. Exposure to high dosage trihexyphenidyl during pregnancy for treatment of generalized dystonia: case report and literature review. The neurologist. 2011 Nov:17(6):340-1. doi: 10.1097/NRL.0b013e31822b54d2. Epub
[PubMed PMID: 22045287]
Level 3 (low-level) evidence
[13]
Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002 Jan 8:58(1):11-7
[PubMed PMID: 11781398]
Level 2 (mid-level) evidence
[14]
. Parkinson's disease: summary of updated NICE guidance. BMJ (Clinical research ed.). 2019 Feb 28:364():l961. doi: 10.1136/bmj.l961. Epub 2019 Feb 28
[PubMed PMID: 30819680]
[15]
Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C, Movement Disorder Society Evidence-Based Medicine Committee. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2018 Aug:33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23
[PubMed PMID: 29570866]
[16]
Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Meijer IA. VPS13D Movement Disorder. GeneReviews(®). 1993:():
[PubMed PMID: 30789691]
[17]
Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, Young AS, Degenhardt A, Hong SH, (Systematic Review). The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. The American journal of psychiatry. 2020 Sep 1:177(9):868-872. doi: 10.1176/appi.ajp.2020.177901. Epub
[PubMed PMID: 32867516]
Level 1 (high-level) evidence
[18]
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2019 Apr:67(4):674-694. doi: 10.1111/jgs.15767. Epub 2019 Jan 29
[PubMed PMID: 30693946]
[19]
Hayashi K, Asano R, Sato M, Nakaya Y, Suzuki A, Takaku N, Hayashi K, Kobayashi Y. Efficacy of Trihexyphenidyl on Apraxia of Eyelid Opening in Parkinsonism: A Case Report. Cureus. 2024 Mar:16(3):e56232. doi: 10.7759/cureus.56232. Epub 2024 Mar 15
[PubMed PMID: 38618350]
Level 3 (low-level) evidence
[20]
Reid SM, Westbury C, Guzys AT, Reddihough DS. Anticholinergic medications for reducing drooling in children with developmental disability. Developmental medicine and child neurology. 2020 Mar:62(3):346-353. doi: 10.1111/dmcn.14350. Epub 2019 Sep 8
[PubMed PMID: 31495925]
[21]
Bradford CV, Parman AM, Johnson PN, Miller JL. Pharmacologic Management of Sialorrhea in Neonatal and Pediatric Patients. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2024:29(1):6-21. doi: 10.5863/1551-6776-29.1.6. Epub 2024 Feb 7
[PubMed PMID: 38332959]
[22]
Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. Current opinion in ophthalmology. 2007 Mar:18(2):129-33
[PubMed PMID: 17301614]
Level 3 (low-level) evidence
[23]
Chiappini S, Mosca A, Miuli A, Semeraro FM, Mancusi G, Santovito MC, Di Carlo F, Pettorruso M, Guirguis A, Corkery JM, Martinotti G, Schifano F, Di Giannantonio M. Misuse of Anticholinergic Medications: A Systematic Review. Biomedicines. 2022 Feb 1:10(2):. doi: 10.3390/biomedicines10020355. Epub 2022 Feb 1
[PubMed PMID: 35203563]
Level 1 (high-level) evidence
[24]
López-Álvarez J, Sevilla-Llewellyn-Jones J, Agüera-Ortiz L. Anticholinergic Drugs in Geriatric Psychopharmacology. Frontiers in neuroscience. 2019:13():1309. doi: 10.3389/fnins.2019.01309. Epub 2019 Dec 6
[PubMed PMID: 31866817]
[25]
Huang Y, Zhao Z, Wei X, Zheng Y, Yu J, Zheng J, Wang L. Long-term trihexyphenidyl exposure alters neuroimmune response and inflammation in aging rat: relevance to age and Alzheimer's disease. Journal of neuroinflammation. 2016 Jul 1:13(1):175. doi: 10.1186/s12974-016-0640-5. Epub 2016 Jul 1
[PubMed PMID: 27411393]
[26]
Begbie F, Walker G, Kubba H, Sabharwal A. Acute colonic pseudo-obstruction in a child taking trihexyphenidyl for drooling: Prescribers beware. International journal of pediatric otorhinolaryngology. 2015 Jun:79(6):932-934. doi: 10.1016/j.ijporl.2015.03.027. Epub 2015 Apr 7
[PubMed PMID: 25912627]
[27]
Jamshidi N, Dawson A. The hot patient: acute drug-induced hyperthermia. Australian prescriber. 2019 Feb:42(1):24-28. doi: 10.18773/austprescr.2019.006. Epub 2019 Feb 1
[PubMed PMID: 30765906]
[28]
Gueta I, Markovits N, Halkin H, Loebstein R. Concomitant oral potassium chloride and anticholinergic therapy is associated with upper gastrointestinal bleeding: A cohort study. British journal of clinical pharmacology. 2021 Apr:87(4):2064-2069. doi: 10.1111/bcp.14616. Epub 2020 Nov 16
[PubMed PMID: 33068044]
[29]
Lefaucheur R, Le Goff F, Gaillon G, Triquenot-Bagan A, Maltête D. Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction? Presse medicale (Paris, France : 1983). 2015 Nov:44(11):1203-4. doi: 10.1016/j.lpm.2015.09.007. Epub
[PubMed PMID: 26433836]
[30]
Torrents R, Ferré JF, Konareff A, Hemery P, Sherwin K, Lassalle C, Simon N, Scerra S. Misuse of Trihexyphenidyl (Artane) on Réunion Island. Journal of clinical psychopharmacology. 2018 Jun:38(3):250-253. doi: 10.1097/JCP.0000000000000882. Epub
[PubMed PMID: 29620695]
[31]
Guru S, Vanamoorthy U, Loganathan S, Varghese M. Neuroleptic malignant syndrome following abrupt anti-cholinergic withdrawal: a case report. Asian journal of psychiatry. 2014 Dec:12():158-9. doi: 10.1016/j.ajp.2014.05.007. Epub 2014 Jun 2
[PubMed PMID: 25440569]
Level 3 (low-level) evidence
[32]
Zhao J, Xu G, Feng C, Chen Y, Kang Y, Liu F, Ma W. Trihexyphenidyl induced malignant hyperthermia in a patient with Parkinson's disease complicated with pneumonia: A case report. Medicine. 2020 May:99(20):e20129. doi: 10.1097/MD.0000000000020129. Epub
[PubMed PMID: 32443324]
Level 3 (low-level) evidence
[33]
Mahal P, Nishanth KN, Mahapatra A, Sarkar S, Balhara YPS. Trihexyphenidyl Misuse in Delusional Disorder. Journal of neurosciences in rural practice. 2018 Jul-Sep:9(3):428-430. doi: 10.4103/jnrp.jnrp_569_17. Epub
[PubMed PMID: 30069107]
[34]
Frauger E, Thirion X, Chanut C, Natali F, Debruyne D, Saillard C, Pradel V, Reggio P, Micallef J. [Misuse of trihexyphenidyl (Artane, Parkinane): recent trends]. Therapie. 2003 Nov-Dec:58(6):541-7
[PubMed PMID: 15058500]
[35]
Ponnapalli A, Grando A, Murcko A, Wertheim P. Systematic Literature Review of Prescription Drug Monitoring Programs. AMIA ... Annual Symposium proceedings. AMIA Symposium. 2018:2018():1478-1487
[PubMed PMID: 30815193]
Level 1 (high-level) evidence
[36]
Petković S, Durendić-Brenesel M, Dolai M, Samojlik I. Fatal intoxication because of trihexyphenidyl. Journal of forensic sciences. 2011 Sep:56(5):1383-6. doi: 10.1111/j.1556-4029.2011.01816.x. Epub 2011 Jun 3
[PubMed PMID: 21644988]
[37]
Freeman PR, Curran GM, Drummond KL, Martin BC, Teeter BS, Bradley K, Schoenberg N, Edlund MJ. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study. Research in social & administrative pharmacy : RSAP. 2019 Jun:15(6):754-760. doi: 10.1016/j.sapharm.2018.09.007. Epub 2018 Sep 14
[PubMed PMID: 30243575]
Level 2 (mid-level) evidence
[38]
Curry SC, Brooks DE, Skolnik AB, Gerkin RD, Glenn S. Effect of a medical toxicology admitting service on length of stay, cost, and mortality among inpatients discharged with poisoning-related diagnoses. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2015 Mar:11(1):65-72. doi: 10.1007/s13181-014-0418-z. Epub
[PubMed PMID: 25127915]